scPharmaceuticals Inc. (SCPH) financial statements (2021 and earlier)

Company profile

Business Address 2400 DISTRICT AVENUE
BURLINGTON, MA 01803
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments738479838995101
Cash and cash equivalents738479838995101
Receivables0010000
Prepaid expense3122212
Other current assets0000000
Total current assets:768582869297103
Noncurrent Assets
Operating lease, right-of-use asset11  
Property, plant and equipment0000000
Restricted cash and investments0000000
Other undisclosed noncurrent assets0011222
Total noncurrent assets:2222222
TOTAL ASSETS:778783889499105
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5896445
Accounts payable1110122
Accrued liabilities4775323
Debt0054332
Restructuring reserve  0    
Other undisclosed current liabilities  00000
Total current liabilities:581410777
Noncurrent Liabilities
Long-term debt and lease obligation202056767
Long-term debt, excluding current maturities191956767
Operating lease, liability11  
Liabilities, other than long-term debt1100000
Other liabilities0000000
Derivative instruments and hedges, liabilities11     
Other undisclosed noncurrent liabilities  11112
Total noncurrent liabilities:212167889
Total liabilities:26292017151516
Stockholders' equity
Stockholders' equity attributable to parent51586370798389
Common stock0000000
Additional paid in capital181177176176175175174
Accumulated deficit(129)(119)(112)(105)(96)(91)(86)
Total stockholders' equity:51586370798389
TOTAL LIABILITIES AND EQUITY:778783889499105

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:0      
Operating expenses(10)(6)(7)(9)(5)(6)(10)
Other undisclosed operating loss(0)      
Operating loss:(10)(6)(7)(9)(5)(6)(10)
Nonoperating income0000000
Investment income, nonoperating0000000
Other nonoperating income (expense)(0)0(0)(0)0(0)(0)
Interest and debt expense(1)(0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(11)(6)(7)(9)(5)(6)(10)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(11)(6)(7)(9)(5)(6)(10)
Comprehensive loss, net of tax, attributable to parent:(11)(6)(7)(9)(5)(6)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: